Efficacy and safety of tixagevimab-cilgavimab (Evusheld ®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence
ConclusionsThese results further support EVS safety and efficacy in boosting anti-TSP IgG titers in pwMS on OCR, with a statistically greater increase than that observed after completion of a full Covid-19 vaccine cycle, plus a booster dose.
Source: Neurological Sciences - Category: Neurology Source Type: research
More News: Brain | Covid Vaccine | COVID-19 | Drugs & Pharmacology | Multiple Sclerosis | Neurology | SARS | Statistics | Study | Vaccines